Abstract PO-066: High uptake, retention, and in vivo activity of L-Annamycin in pancreatic cancer models

Author(s):  
Ya'an Kang ◽  
Rafal Zielinski ◽  
Roberto Cardenas Zuniga ◽  
Radjendirane Venugopal ◽  
Maria Poimenidou ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 930
Author(s):  
Donatella Delle Cave ◽  
Riccardo Rizzo ◽  
Bruno Sainz ◽  
Giuseppe Gigli ◽  
Loretta L. del Mercato ◽  
...  

Pancreatic cancer, the fourth most common cancer worldwide, shows a highly unsuccessful therapeutic response. In the last 10 years, neither important advancements nor new therapeutic strategies have significantly impacted patient survival, highlighting the need to pursue new avenues for drug development discovery and design. Advanced cellular models, resembling as much as possible the original in vivo tumor environment, may be more successful in predicting the efficacy of future anti-cancer candidates in clinical trials. In this review, we discuss novel bioengineered platforms for anticancer drug discovery in pancreatic cancer, from traditional two-dimensional models to innovative three-dimensional ones.


Nutrients ◽  
2017 ◽  
Vol 9 (4) ◽  
pp. 331 ◽  
Author(s):  
Concetta Panebianco ◽  
Kaarel Adamberg ◽  
Signe Adamberg ◽  
Chiara Saracino ◽  
Madis Jaagura ◽  
...  

2014 ◽  
Vol 111 (2) ◽  
pp. 318-325 ◽  
Author(s):  
T E Bapiro ◽  
K K Frese ◽  
A Courtin ◽  
J L Bramhall ◽  
B Madhu ◽  
...  

Oncotarget ◽  
2015 ◽  
Vol 6 (21) ◽  
pp. 18545-18557 ◽  
Author(s):  
Martina D’Aronzo ◽  
Manlio Vinciguerra ◽  
Tommaso Mazza ◽  
Concetta Panebianco ◽  
Chiara Saracino ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 9 (12) ◽  
pp. 10457-10469 ◽  
Author(s):  
Jiyan Mohammad ◽  
Harsharan Dhillon ◽  
Shireen Chikara ◽  
Sujan Mamidi ◽  
Avinash Sreedasyam ◽  
...  

Nanomaterials ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 438
Author(s):  
Felista L. Tansi ◽  
Filipp Fröbel ◽  
Wisdom O. Maduabuchi ◽  
Frank Steiniger ◽  
Martin Westermann ◽  
...  

Magnetic hyperthermia can cause localized thermal eradication of several solid cancers. However, a localized and homogenous deposition of high concentrations of magnetic nanomaterials into the tumor stroma and tumor cells is mostly required. Poorly responsive cancers such as the pancreatic adenocarcinomas are hallmarked by a rigid stroma and poor perfusion to therapeutics and nanomaterials. Hence, approaches that enhance the infiltration of magnetic nanofluids into the tumor stroma convey potentials to improve thermal tumor therapy. We studied the influence of the matrix-modulating enzymes hyaluronidase and collagenase on the uptake of magnetic nanoparticles by pancreatic cancer cells and 3D spheroids thereof, and the overall impact on magnetic heating and cell death. Furthermore, we validated the effect of hyaluronidase on magnetic hyperthermia treatment of heterotopic pancreatic cancer models in mice. Treatment of cultured cells with the enzymes caused higher uptake of magnetic nanoparticles (MNP) as compared to nontreated cells. For example, hyaluronidase caused a 28% increase in iron deposits per cell. Consequently, the thermal doses (cumulative equivalent minutes at 43 °C, CEM43) increased by 15–23% as compared to heat dose achieved for cells treated with magnetic hyperthermia without using enzymes. Likewise, heat-induced cell death increased. In in vivo studies, hyaluronidase-enhanced infiltration and distribution of the nanoparticles in the tumors resulted in moderate heating levels (CEM43 of 128 min as compared to 479 min) and a slower, but persistent decrease in tumor volumes over time after treatment, as compared to comparable treatment without hyaluronidase. The results indicate that hyaluronidase, in particular, improves the infiltration of magnetic nanoparticles into pancreatic cancer models, impacts their thermal treatment and cell depletion, and hence, will contribute immensely in the fight against pancreatic and many other adenocarcinomas.


Pancreatology ◽  
2014 ◽  
Vol 14 (3) ◽  
pp. S110
Author(s):  
Valerio Pazienza ◽  
Manlio Vinciguerra ◽  
Martina D'Aronzo ◽  
Tommaso Mazza ◽  
Angelo Andriulli

2015 ◽  
Vol 757 ◽  
pp. 59-67 ◽  
Author(s):  
Chern Ein Oon ◽  
Carina Strell ◽  
Keng Yoon Yeong ◽  
Arne Östman ◽  
Jai Prakash

2020 ◽  
Vol 8 (Suppl 2) ◽  
pp. A43.2-A43
Author(s):  
AM Senz ◽  
P Metzger ◽  
RK Rubens ◽  
B Cadilha ◽  
M Kirmaier ◽  
...  

BackgroundIndoleamine-2,3-dioxygenase 1 (IDO1) is a cytosolic enzyme that catalyzes the rate limiting reaction in the kynurenine pathway. Dendritic cells, macrophages and several tumor entities have been described to express IDO1. In the tumor microenvironment IDO1 promotes tryptophan starvation and accumulation of kynurenines which result in T effector cell proliferation arrest and T regulatory cell induction. Additionally, IDO1 possesses two immunoreceptor tyrosine-based inhibitory motifs (ITIM) that upon phosphorylation can act as docking sites for the recruitment and activation of the tyrosine phosphatases SHP–1 and SHP–2 and ultimately to an activation of the non-canonical NF-ΚB pathway. Whether IDO1 is expressed in T cells and its potential function is unknown.Materials and MethodsUsing IDO1-deleted splenocytes from CD4-Cre Ido1fl/fl mice and WT controls, we evaluated the induction of IDO1 in T cells, as well as the effect of IDO1 in T cell proliferation, differentiation and metabolism. Additionally, we compared in vitro and in vivo the cytotoxic activity of anti-epithelial cell adhesion molecule (EpCAM) chimeric antigen receptor (CAR) T cells using pancreatic tumor cell lines.ResultsIDO1 is inducible in primary mouse T cells upon T cell activation and type I and type II interferon signaling. Interestingly, the use of IDO1 knockout CAR T cells prolongs survival and improves tumor control compared to WT CAR T cell treatment in subcutaneous and orthotopic pancreatic cancer models. In vitro, T cell proliferation, differentiation and cytotoxic function is comparable in WT and IDO1-deleted T cells. RNA sequencing, metabolic and in vivo tracking studies are currently being performed to pin down IDO1-intrinsic effects on CAR T cells.ConclusionsIDO1 is expressed in T cells upon T cell receptor and IFN stimulation and appears to negatively affect tumor control mediated by CAR T cells. Specific IDO1 deletion may improve therapeutic efficacy of CAR T cells in solid tumors, such as pancreatic cancer.Disclosure InformationA.M. Senz: None. P. Metzger: None. R.K. Rubens: None. B. Cadilha: None. M. Kirmaier: None. S. Lesch: None. M.R. Benmebarek: None. S. Theurich: None. P. Murray: None. S. Endres: None. S. Kobold: None. L.M. König: None. P. Duewell: None. M. Schnurr: None.


Sign in / Sign up

Export Citation Format

Share Document